Sethera Therapeutics, Inc.
Biotechnology company developing an enzymatic platform for synthesis and discovery of polymacrocyclic peptides. The platform uses radical S-adenosyl-L-methionine (radical SAM) maturase-based biocatalysis to install thioether linkages and generate diverse, stable macrocyclic architectures. The organization supports partner collaborations for library construction, target screening, and late-stage enzymatic peptide modification, and publishes peer-reviewed research and patents describing the underlying enzymology and applications.
Industries
N/A
Nr. of Employees
small (1-50)
Products
PolyMacrocyclic peptide Discovery Platform
A proprietary drug discovery platform utilizing enzymatic cross-linking technology to synthesize and engineer stable, polymacrocyclic peptides (pMCPs) with unique architectures and chemistries for targets of all kinds.
PolyMacrocyclic peptide Discovery Platform
A proprietary drug discovery platform utilizing enzymatic cross-linking technology to synthesize and engineer stable, polymacrocyclic peptides (pMCPs) with unique architectures and chemistries for targets of all kinds.
Services
Design and enzymatic construction of polymacrocyclic peptide libraries and support for compatibility with phage, mRNA display and DNA-encoded library screening; pooling and sequencing workflows for hit identification.
Application of sequence-agnostic enzymatic macrocyclization methods to convert linear peptide candidates into stabilized macrocyclic forms for therapeutic development.
Design and enzymatic construction of polymacrocyclic peptide libraries and support for compatibility with phage, mRNA display and DNA-encoded library screening; pooling and sequencing workflows for hit identification.
Application of sequence-agnostic enzymatic macrocyclization methods to convert linear peptide candidates into stabilized macrocyclic forms for therapeutic development.
Expertise Areas
- Polymacrocyclic peptide discovery
- Enzymatic peptide macrocyclization
- Biocatalysis and enzyme engineering
- Macrocycle library construction and display screening
Key Technologies
- Radical S-adenosyl-L-methionine (radical SAM) enzymatic macrocyclization
- Thioether ligation
- Noncanonical amino acid incorporation
- Combinatorial macrocycle library construction
News & Updates
Company presentation at the 2025 E&I Summit; speaker Karsten Eastman presented on company technology.
Peer-reviewed article describing use of a radical SAM maturase to generate diverse thioether macrocyclized peptides and establishing sequence-agnostic C-terminal macrocyclization.
Article describing leader-independent activity of a radical SAM maturase applied to GLP-1–like peptides to generate C-terminal thioether macrocycles.
Third-party news summary describing enzymatic macrocyclization as a route to improved GLP-1–pathway agonists.
Published patent disclosing methods for installing thioether linkages in peptides using a biocatalyst.
Appointment of prominent scientists to the scientific advisory board and leadership roles, indicating external scientific validation and advisory support.
Company presentation at the 2025 E&I Summit; speaker Karsten Eastman presented on company technology.
Peer-reviewed article describing use of a radical SAM maturase to generate diverse thioether macrocyclized peptides and establishing sequence-agnostic C-terminal macrocyclization.
Article describing leader-independent activity of a radical SAM maturase applied to GLP-1–like peptides to generate C-terminal thioether macrocycles.
Third-party news summary describing enzymatic macrocyclization as a route to improved GLP-1–pathway agonists.
Published patent disclosing methods for installing thioether linkages in peptides using a biocatalyst.
Appointment of prominent scientists to the scientific advisory board and leadership roles, indicating external scientific validation and advisory support.